Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome

19Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Rett syndrome (RTT) is caused by loss-of-function mutations in the X-linked gene MECP2 coding for methyl CpG-binding protein 2 (MeCP2). This protein can act as transcriptional repressor, and we showed in a previous study that glucocorticoid-inducible genes are up-regulated in an RTT mouse model and that these genes are direct MeCP2 targets. Here, we report that pharmacological intervention with the glucocorticoid system has an impact on the symptoms and lifespan in an RTT mouse model. Our data support a functional implication of the stress hormone system in RTT and suggest this hormone system as potential therapeutic target. © The Author 2011. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Braun, S., Kottwitz, D., & Nuber, U. A. (2012). Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome. Human Molecular Genetics, 21(8), 1673–1680. https://doi.org/10.1093/hmg/ddr602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free